Key Highlights

• General Influenza diagnostics refers to the methods, tests, and procedures used by doctors to diagnose and confirm flu in patients. Influenza, also known as influenza, is a respiratory disease caused by the influenza virus. Rapid and accurate diagnosis is essential for timely treatment, patient management, and public health monitoring. These tests include many techniques. Rapid fever tests (RIDT) are often used in clinical settings and provide rapid results, usually within 15-30 minutes, but they may have limits on sensitivity. The polymerase chain reaction (PCR) test is a highly effective and specific molecular test that detects genetic factors and ensures that the virus is infected. PCR testing is particularly useful for confirming cases of influenza and tracking specific subtypes of the virus. Bacterial culture can also be used to isolate and identify influenza viruses, although this method is time-consuming and rarely used in modern medicine. Serology tests the body's antibodies to the flu and can provide information about past infections and immunity. These tests allow doctors to quickly diagnose influenza, administer appropriate treatment, initiate preventive measures, and provide important information for public surveillance and response to influenza.

• The market size of the worldwide General Influenza Diagnostics Industry surpassed USD XX Billion in 2023, and by 2032, it is projected to reach USD XX billion, boosting at a CAGR of XX%.

• In August 2022, Seegene launched a campaign to provide routine PCR tests for COVID-19, influenza A and B, and respiratory syncytial virus (RSV) in certain contexts in the European and Asian markets. The Lifetime PCR Program was created “in advance” to reduce the spread of COVID-19 and other respiratory diseases through public health measures and increased travel.

• Demand for widespread flu testing is driven by a number of factors, primarily focused on public health concerns, timely patient care, and planning. First of all, the danger of seasonal flu and the potential for large-scale epidemics emphasize the importance of early diagnosis. Reducing the spread of disease in communities and healthcare facilities. Second, international travel has increased the need for accurate diagnosis. Flu can spread very quickly between regions and countries, and its effective detection and spread requires good diagnostic equipment. Timely diagnosis is important to prevent large-scale transmission, especially in crowded areas and during gatherings. Three, advances in technology such as PCR and ongoing research and development in influenza diagnosis, including the development of rapid and accurate antibody tests of diseases, help support the needs. These innovations have improved the overall results of diagnosing influenza by improving the sensitivity and specificity of the diagnostic method and distinguishing it from other respiratory diseases. In addition, with increasing awareness of flu, as well as government policies and health plans encouraging people to seek timely diagnosis and treatment, drivers need flu testing. As healthcare systems around the world focus on early detection, diagnosis and rapid response, the need for accurate and effective flu testing continues to grow to control the flu epidemic and reduce its impact on public health.

Scope of the Industry Profile

Key Players

• Thermo Fisher Scientific (US)

• Hologic (US)

• Quidel Corporation (US)

• F. Hoffmann-La Roche AG (Switzerland)

• Abbott Laboratories (US)

• Becton (US)

• Dickinson and Company (US)

• Danaher Corporation (US)

• Meridian Bioscience (US)

• BioMérieux SA (US)

Segmentation

By End User

• Hospitals & Clinical Laboratories

• Diagnostic Reference Laboratories

• Academic & Research Institutes

By Molecular Tests

• Reverse Transcription Polymerase Chain

• Reaction (RT-PCR)

• Isothermal Nucleic Acid Amplification Tests (INAAT)

• Loop-Mediated Isothermal-based Amplification Assays

• Transcription Mediated Isothermal-based Amplification Assays

• Other Molecular Tests

By Traditional Tests

• Rapid Influenza Diagnostic Tests (RIDTs)

• Direct Fluorescent Antibody (DFA) Tests

• Viral Culture

• Serological Assays

By Test Type

• Traditional Diagnostic Tests

• Molecular Diagnostic Test

What to Expect from Industry Profile

1. Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the General Influenza Diagnostics market in the world.

2. Use the PORTER’s Five Forces analysis to determine the competitive intensity and therefore market attractiveness of the Global General Influenza Diagnostics market.

3. Leading company profiles reveal details of key General Influenza Diagnostics market players’ global operations, strategies, financial performance & their recent developments.

4. Add weight to presentations and pitches by understanding the future growth prospects of the Global General Influenza Diagnostics market with forecast for decade by both market share (%) & revenue (USD Million).

Recent Development

• June 2022, BD MAX Respiratory Virus Panel (RVP, according to a statement from BD) is a new test for the molecular diagnosis of SARS-CoV-2, Influenza A + Influenza B and Respiratory Syncytial Virus (RSV) panel test , CE marked according to IVD Directive 98/79/EC (Beckton Dickinson).

Segment Insights

By End User

The demand for more flu testing in hospitals and clinics is driven primarily by the important role these tests play in patient care, infection control, and public health. First, hospitals and diagnostic laboratories are at the forefront of patient care. Rapid and accurate diagnosis of fever is important for early diagnosis and timely initiation of antiretroviral therapy, especially for vulnerable people such as the elderly and patients. Timely diagnosis helps doctors make informed decisions about patient management and appropriate interventions. Secondly, disease control is important in treatment. Influenza spreads rapidly, and early diagnosis of patients can help implement appropriate isolation procedures and preventive measures to prevent further spread in healthcare facilities. Rapid diagnosis of influenza is an important tool to prevent and treat influenza resulting from other respiratory diseases and can guide effective infection control strategies. For us, these tests are very important for public health monitoring. Hospitals and laboratories provide important information for monitoring influenza, identifying outbreaks, and recommending vaccination strategies. Accurate diagnosis helps track the spread of the disease, allowing the government to assess the severity of the disease and allocate resources effectively. Additionally, continuing advances in diagnostic technology, including point-of-care monitoring and molecular testing, are increasing the efficiency and accuracy of influenza diagnosis in hospitals and laboratories and strengthening needs in critical care facilities.

By Traditional Tests

The need for rapid influenza diagnostic tests (RIDTs) for general influenza diagnosis is driven by the critical need for rapid, immediate results, particularly in clinical settings and influenza whenever possible. First, RIDT provides rapid results, usually within 15-30 minutes, allowing doctors to quickly diagnose flu. This speed is important for timely intervention, especially in hospitals and clinics where anti-inflammatory therapy and appropriate patient management can be initiated immediately, which may affect patient outcomes. Second, RIDTs are required in emergency rooms, emergency rooms, and outpatient clinics. Patients with flu-like symptoms can be diagnosed quickly, helping to make immediate decisions about isolation options, treatment plans and preventing cross-contamination within facilities. We, as RIDT, are important in flu epidemics and important screening events. In this case, these tests can quickly evaluate large numbers of people, helping public health authorities implement measures such as isolation and timely vaccination. In addition, RIDT is user-friendly and does not require complex laboratory work. This ease of use makes them desirable, allowing them to be used in many medical facilities, including remote areas or restricted areas. Overall, the speed, accessibility, and immediate results of RIDT are desirable for influenza diagnosis, allowing rapid response to influenza and epidemics.

Regional Insights

The need for more flu testing in North America is driven by several factors. First, the region experiences influenza every year, thus increasing the need for diagnostic equipment. Rapid and accurate diagnosis is critical to enable timely treatment in healthcare, reduce hospitalizations, and prevent community transmission. Second, North America faces the threat of a possible flu epidemic. As preparedness increases, effective diagnostic capabilities are needed to identify and monitor influenza. Effective diagnosis facilitates early detection and enables rapid response measures, such as vaccines and antiretroviral therapy, to reduce the impact of infectious disease. We help meet the needs of the region with its advanced medical and technological resources. North America is at the forefront of medical research and innovation, leading the development and application of new technologies. These advances provide doctors with access to specialized diagnostic tools that increase the accuracy of influenza diagnosis. In addition, public awareness campaigns and education campaigns highlight the importance of rapid tests, encouraging people to seek treatment and get tested quickly. Government surveillance measures are increasing demand for flu testing, simplifying decision-making and public health interventions. Therefore, there remains a need for accurate, rapid, and effective influenza testing in North America.